To disclose a method of reducing neovascularization and a method of treating various disorders associated with neovascularization.
A pharmaceutical composition for inhibiting neovascularization comprises a synthetic oligonuleotide which is specific to the nucleic acid sequence of the vascular endothelial growth factor and specifically inhibits the expression of the vascular endothelial growth factor and a physiologically acceptable carrier. and the oligonucleotide has at least one internucleotide bonding selected from the group consisting of a phosphorodithioate, a phosphoric ester, a carbamate, an acetamidate, a carboxymethyl ester, a carbonate, and a phosphoric triester. The oligonucleotide which is specific to the nucleic acid of the vascular endothelial growth factor and effective in inhibiting the expression of the vascular endothelial growth factor in the retina is used for producing the pharmaceutical composition for treating retinopathy of prematurity and age-related macular degeneration.
SMITH LOIS ELAINE HODGSON
CHILDRENS MEDICAL CENTER
Samejima Mutsumi
Nagatoshi Shinagawa
Shinichiro Yamanaka